Ritanserin in Treatment of Cocaine Dependence - 1

This study has been completed.

First Received: September 20, 1999 Last Updated: August 16, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000187

Purpose

The purpose of this study is to assess ritanserin as a pharmacotherapy for cocaine dependence.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Ritanserin	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Ritanserin in Treatment of Cocaine Dependence

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride Ritanserin

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Cocaine use
Cocaine craving

Estimated Enrollment:	0
Study Start Date:	July 1992

Eligibility

Ages Eligible for Study:	28 Years to 47 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000187

Locations

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

James Cornish, M.D.

University of Pennsylvania

More Information

No publications provided

Study ID Numbers:	NIDA-00144-1, K20-00144-1
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000187 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Disorders of Environmental Origin
Ritanserin
Antipsychotic Agents

Pharmacologic Actions
Serotonin Antagonists
Serotonin Agents
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Anti-Anxiety Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on November 22, 2009